Fujian Haixi Pharmaceuticals Co., Ltd.
2637.HK
Hong Kong Stock Exchange213.80
HKD
+6.60
- -
ISIN
CNE100007515
Return %
Stock
S&P500
1Y
63.96
21.04
3Y
63.96
71.31
5Y
63.96
72.92
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Xinshan Kang
- Full Time Employees
- 200
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Floor 3 & 4, Block B Fuzhou People's Republic of China 350028
- IPO Date
- Dec 8, 2025
- Website
- hxpharma.com
- Similar Companies
- Business
- Fujian Haixi Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of generic and innovative drugs, with a focus on therapeutic areas including digestive, cardiovascular, endocrine, nervous system, inflammatory, oncology, ophthalmology, and respiratory diseases; the company operates primarily in the domestic Chinese market, with expanding R&D into innovative drug candidates and a pipeline that includes multiple candidates across oncology and ophthalmology indications. The company is headquartered in Fujian Province, China, and is publicly listed on the Hong Kong Stock Exchange (ticker 2637.HK); it was founded to develop, manufacture, and commercialize pharmaceutical products for broad patient needs and to advance its integrated drug development platform. Main products and services include: generic pharmaceuticals across digestive, cardiovascular, endocrine, nervous system, and inflammatory indications; innovative drug candidates in development, including early- and late-stage clinical programs; contract development and manufacturing services (CDMO) for pharmaceutical products; wholesale and distribution of pharmaceutical products within mainland China; import/export of pharmaceutical ingredients and finished dosages; pharmaceutical logistics and related support services; veterinary drug products and veterinary drug sales; cosmetics production and sales. The company’s strategic activity over the last 1–2 years includes partnerships and collaborations to advance its innovative pipeline, funding and capital market activities surrounding its Hong Kong listing, potential acquisitions or strategic investments to expand its manufacturing capacity and geographic reach, and ongoing organizational refinements to align with its dual focus on generics and innovative therapies. The latest changes emphasize accelerated development of its in-house pipeline with notable candidates such as multi-mechanism tumor immuno-modulators and potential first oral therapies for ocular fundus diseases, alongside continued expansion of domestic manufacturing capabilities, regulatory submissions for ANDAs and in-house product launches, and enhanced collaboration with external partners to accelerate commercialization in China and select international markets. The company’s product portfolio includes Anbili, Haihuitong, Ruiantuo, and Saixifu as core brands within its generic suite, plus an extensive late-stage or early-stage innovative program targeting oncology, ophthalmology, and other major therapeutic areas; geographic operations concentrate on the Chinese market, with potential cross-border development and export opportunities consistent with its import/import-export and overseas collaboration capabilities. The business model combines in-house manufacturing with contract manufacturing and services, enabling a diversified revenue base from domestic sales, export activities, and fee-based development services, while pursuing strategic partnerships to monetize its innovative pipeline and bolster manufacturing scale. The company’s ownership structure points to a controlling interest associated with its founder-entrepreneur leadership and a corporate governance framework aligned with listed Chinese-GAAP/IFRS disclosures, as evidenced by recent capital markets filings detailing project pipelines, regulatory approvals, and corporate reorganizations.